Kidneys dominate the transplant waiting list — in the United States they account for roughly eight of every ten people waiting. They are also, by most measures, the hardest organ in the body to bioprint. That combination of highest demand and highest difficulty defines the whole problem.
What a kidney actually is
Each human kidney contains roughly one million nephrons. A nephron is not a simple filter; it is a sequence of specialised segments, each performing a different transport function in a different order, wrapped around a tuft of capillaries and threaded through a tissue with a carefully arranged gradient of salt concentration from the outside of the organ to its centre.
More than twenty distinct cell types are involved. The organ receives about a fifth of the body's entire cardiac output, which means its vascular density is extreme even by the standards of solid organs. And the architecture is not decorative — the counter-current arrangement of the loops of Henle alongside their blood vessels is precisely what allows urine to be concentrated. Get the geometry wrong and the chemistry does not work.
This is why "print a kidney" is not a scaled-up version of "print a piece of cartilage". The function is inseparable from a microscopic three-dimensional arrangement that no current printer can produce, at a scale of a million repeating units.
Kidney organoids and printed organoids
The most productive line of work has come from a different direction: instead of printing the architecture, let the cells build it themselves.
Kidney organoids are small, self-organising structures grown from pluripotent stem cells that spontaneously form nephron-like segments. Melissa Little's group, at the Murdoch Children's Research Institute in Melbourne, developed protocols that reliably produce them, and then went further: in work published in 2021 they used extrusion bioprinting to manufacture kidney organoids at scale, with far more consistent cell numbers and far less manual handling than hand-plating allows.
That study also showed something useful and slightly counter-intuitive — the printed geometry of the starting cell patch changed how the resulting organoid developed, meaning printing was not merely an automation convenience but a way to steer differentiation.
Organoids are, however, millimetre-scale and lack a connected blood supply, a collecting system and mature function. They are outstanding research tools and not proto-transplants.
Printed nephron tubules
A second line of work builds individual functional units rather than whole organs. Jennifer Lewis's laboratory at Harvard has printed perfusable proximal tubules embedded in an extracellular-matrix gel, lined with kidney epithelial cells, alongside separately printed vascular channels lined with endothelial cells.
These constructs demonstrate real physiology: selective reabsorption between the tubule and the adjacent vessel, and measurable responses to nephrotoxic drugs. They are, in effect, printed kidney-on-a-chip systems — and as drug-testing platforms they are commercially meaningful right now.
What printed kidney tissue is used for today
The kidney is the organ most often damaged by drug toxicity, and animal models predict human kidney toxicity poorly. Printed human kidney tissue and organoids are used to:
- screen drug candidates for nephrotoxicity before human exposure;
- model genetic kidney disease — polycystic kidney disease organoids from patient cells reproduce cyst formation in a dish;
- test whether a candidate therapy corrects a defect in that patient's own cells;
- study kidney development and regeneration.
None of this replaces a transplant. All of it has clear commercial value now, which is why it, rather than organ replacement, funds most of the work.
The specific obstacles
| Obstacle | The problem in concrete terms |
|---|---|
| Nephron count | A million functional units per kidney, each requiring correct internal segmentation. Printing them individually is not feasible; growing them requires solving self-organisation at scale. |
| Vascular density | The glomerular capillary tuft is a specialised filtration structure only a few micrometres across. No printing method approaches that geometry. |
| Cell diversity | More than twenty cell types, each of which must appear in the right place and stay there. |
| Collecting system | Filtrate has to leave. That means printing a connected ureteric tree and joining it surgically to the bladder. |
| Corticomedullary gradient | Concentrating urine depends on a salt gradient produced by tissue architecture, not by any single cell. |
| Immunological safety | Even patient-derived tissue must be shown not to form teratomas — a real risk with pluripotent-stem-cell-derived products. |
Competing approaches
Bioprinting is not the only route to solving kidney scarcity, and for the foreseeable future it is probably not the leading one.
- Xenotransplantation. Gene-edited pig kidneys have been transplanted into brain-dead donors and, since 2024, into living patients. Progress here has been much faster than in bioprinting, though long-term outcomes remain the open question.
- Decellularised scaffolds. Strip a donor or animal kidney of its cells, leaving the matrix and its entire vascular tree intact, then reseed it with the recipient's cells. This neatly sidesteps the vascular printing problem, at the cost of still needing a donor organ to start from.
- Implantable bioartificial kidneys. Silicon nanopore filters combined with a bioreactor of living kidney cells, designed as an implantable device rather than an organ. The Kidney Project, a collaboration between UCSF and Vanderbilt, has pursued this for years.
The most likely near-term contribution of bioprinting to kidney disease is not a printed kidney at all. It is better drug screening, better disease models, and possibly printed tissue patches that support a failing kidney rather than replacing it.
Related
- All printed organsThe full status report
- Waiting list dataWhy kidneys dominate the numbers
- LiverThe other metabolic organ
- GlossaryOrganoid, nephron, decellularisation
Last reviewed . Educational information only — not medical advice.